Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrationsMore about Open Access at the Crick
Authors listElen Kristine Höglander Silje Nord David C Wedge Ole Christian Lingjaerde Laxmi Silwal-Pandit Hedda vdL Gythfeldt Hans Kristian Moen Vollan Thomas Fleischer Marit Krohn Ellen Schlitchting Elin Borgen Øystein Garred Marit M Holmen Erik Wist Bjørn Naume Peter Van Loo Anne-Lise Børresen-Dale Olav Engebraaten Vessela Kristensen
Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its receptor interaction, thus obstructing the formation of new blood vessels.
Journal Genome Medicine
Issue number 1